A Phase 4 interventional study of JZP-258 in Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 28 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Jazz Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 12th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 120 across the 15 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
Participants who have been taking Xyrem (with or without additional anticataplectics or stimulants eg, TCA, SNRI, SSRI, atomoxetine) in a stable dose and regimen for at least two months prior to screening, with evidence of clinical improvement on their current regimen, per the investigator's judgement. Only Xyrem will be substituted with XYWAV, with dose and regimen of any concomitant anticataplectics or stimulants remaining unchanged throughout the study.
Sex and /Barrier Requirements
Participant is male or female
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
Informed Consent
Exclusion Criteria:
Medical Conditions
Show evidence of untreated or inadequately treated sleep-disordered breathing including:
Are a female participant who is pregnant or breastfeeding
Prior/Concomitant Therapy
Have undergone treatment with any prohibited central nervous system (CNS) agents, including but not limited to benzodiazepines, non-benzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, phenytoin, ethosuximide, or MCT inhibitors, eg, diclofenac, valproate, ibuprofen, within 2 weeks prior to enrollment. Discontinuation for the purpose of study enrollment is permitted only if considered safe by the investigator and approved by the Medical Monitors.
Prior/Concurrent Clinical Study Experience
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conversion from Xyrem to XYWAV, maintaining the dose and regimen of any concomitant anticataplectics or stimulants unchanged throughout study.
Drug: JZP-258
Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
Also known as: XYWAV
Change in Weekly Rate of Cataplexy Attacks
Mean weekly rate of cataplexy attack = (total number of cataplexy attacks reported during the period/number of days during the period where a diary was completed) x 7.
Time frame: Baseline to Week 8
Change in the Nausea Visual Analog Scale (NVAS)
Tolerability associated with Xyrem and XYWAV was measured based on an NVAS assessment administered electronically. NVAS was captured daily during the last 7 days of the Baseline (Xyrem-stable dose and regimen) period and the last 7 days of the Intervention period (on XYWAV) prior to the ET visit or prior to the E/D visit, if possible. For participants with at least one day of NVAS data, the NVAS for that week was the average daily score from days with non-missing data within the week, then multiplied by 7. The NVAS ranges 0-100 mm, with higher scores representing more severe/intense nausea.
Time frame: Baseline to Week 8
Number of Participants With Patient Global Impression of Change (PGIc) Values
The PGIc is a 7-point Likert-type rating based on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). PGIc values were measured at the ET or E/D, as applicable.
Time frame: Week 8
Change in Epworth Sleepiness Scale (ESS)
The ESS questionnaire included a set of 8 questions regarding how likely the participant would be to doze off or fall asleep in different situations. The ESS measures EDS or average sleep propensity in daily life. Responses range from 0 = would never doze (better outcome) to 3 = high chance of dozing (worse outcome). Changes in ESS scores were assessed between the Baseline period and ET or E/D, as applicable
Time frame: Baseline to Week 8
Time to Achieve Optimized Dose and Regimen
Defined as the time from the first dose and regimen to the optimized dose and regimen of XYWAV, where the optimized dose and regimen indicates the final dose and regimen that remains unchanged throughout the remainder of the Intervention period.
Time frame: Baseline to Week 8
Number of Changes From the First Dose and Regimen to Optimized Dose and Regimen
The amount of times the dose and regimen were changed before an optimized dose and regimen were achieved.
Time frame: Baseline to Week 8
Number of Participants Dosing Fasted Versus Dosing Without Consideration of Food
Once the participant reached an optimized dose and regimen, the investigator could decide to instruct the participant to dose without regard to food.
Time frame: Baseline to Week 8
Duration of Time Between the Last Meal Relative to Dosing
The difference between the time of day that participants ate their last meal and the time of day participants take their first dose.
Time frame: Baseline to Week 8
Characterization of Meals Relative to Dosing
Types of meals consumed before dosing.
Time frame: Baseline to Week 8
A total of 62 participants were enrolled in trial sites across the United States.
| Milestone | Overall |
|---|---|
| Started | 62 |
| Baseline period | 62 |
| Intervention (xywav) period | 60 |
| Safety follow-up period | 59 |
| Completed | 54 |
| Not completed | 8 |
| Withdrew: Adverse event | 1 |
| Withdrew: Alcohol or urine drug screen result is positive | 4 |
| Withdrew: Noncompliance with study intervention | 1 |
| Withdrew: Withdrawal by subject | 2 |
Mean weekly rate of cataplexy attack = (total number of cataplexy attacks reported during the period/number of days during the period where a diary was completed) x 7.
| cataplexy attacks per week | Overall |
|---|---|
| Change in Weekly Rate of Cataplexy Attacks | 0.98 ± 4.1222 |
Tolerability associated with Xyrem and XYWAV was measured based on an NVAS assessment administered electronically. NVAS was captured daily during the last 7 days of the Baseline (Xyrem-stable dose and regimen) period and the last 7 days of the Intervention period (on XYWAV) prior to the ET visit or prior to the E/D visit, if possible. For participants with at least one day of NVAS data, the NVAS for that week was the average daily score from days with non-missing data within the week, then multiplied by 7. The NVAS ranges 0-100 mm, with higher scores representing more severe/intense nausea.
| score on a scale | Overall |
|---|---|
| Change in the Nausea Visual Analog Scale (NVAS) | 3.13 ± 29.089 |
The PGIc is a 7-point Likert-type rating based on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). PGIc values were measured at the ET or E/D, as applicable.
| Participants | Overall |
|---|---|
| Very Much Improved | 1 |
| Much Improved | 9 |
| Minimally Improved | 12 |
| No Change | 26 |
| Minimally Worse | 3 |
| Much Worse | 0 |
| Very Much Worse | 0 |
The ESS questionnaire included a set of 8 questions regarding how likely the participant would be to doze off or fall asleep in different situations. The ESS measures EDS or average sleep propensity in daily life. Responses range from 0 = would never doze (better outcome) to 3 = high chance of dozing (worse outcome). Changes in ESS scores were assessed between the Baseline period and ET or E/D, as applicable
| units on a scale | Overall |
|---|---|
| Change in Epworth Sleepiness Scale (ESS) | -0.6 ± 2.33 |
Defined as the time from the first dose and regimen to the optimized dose and regimen of XYWAV, where the optimized dose and regimen indicates the final dose and regimen that remains unchanged throughout the remainder of the Intervention period.
| day | Overall |
|---|---|
| Time to Achieve Optimized Dose and Regimen | 2.6 ± 4.90 |
The amount of times the dose and regimen were changed before an optimized dose and regimen were achieved.
| Participants | Overall |
|---|---|
| Never Changed | 48 |
| Changed Once | 6 |
| Changed Twice | 0 |
| Changed More than Twice | 0 |
Once the participant reached an optimized dose and regimen, the investigator could decide to instruct the participant to dose without regard to food.
| Participants | Overall |
|---|---|
| Dosing Fasted | 53 |
| Dosing without Food Consideration | 1 |
The difference between the time of day that participants ate their last meal and the time of day participants take their first dose.
| minute | Overall |
|---|---|
| Duration of Time Between the Last Meal Relative to Dosing | 113.7 ± 313.31 |
Types of meals consumed before dosing.
| Participants | Overall |
|---|---|
| Regular Meal | 54 |
| Snack | 45 |
| Beverage Other than Water | 19 |
Collected over Treatment-emergent adverse event (TEAE) data were collected from up to 30 days before Day 1 up to week 10 + 3 days.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall | 0/60 (0%) | 2/60 (3.3%) | 18/60 (30%) |
| Event | Overall |
|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 1/60 |
| FallInjury, poisoning and procedural complications | 1/60 |
| Event | Overall |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/60 |
| NauseaGastrointestinal disorders | 2/60 |
| COVID-19Infections and infestations | 2/60 |
| NasopharyngitisInfections and infestations | 2/60 |
| HeadacheNervous system disorders | 2/60 |
| Night sweatsSkin and subcutaneous tissue disorders | 2/60 |
| HaemorrhoidsGastrointestinal disorders | 1/60 |
| ChillsGeneral disorders | 1/60 |
| Oedema peripheralGeneral disorders | 1/60 |
| ConjunctivitisInfections and infestations | 1/60 |
Baseline characteristics were assessed using the Safety Analysis Set, which included all participants in the Enrolled Analysis set who received at least 1 dose of Xyrem after providing informed consent.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 44.3 ± 15.22 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 37 |
| Male | 25 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 58 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 54 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Nov 2022, 19 months.
Results were first posted in Jan 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JZP258